APPROVED FOR THE TREATMENT OF IPF AND SSc-ILD
FACE PULMONARY FIBROSIS
and modify disease progression by slowing lung function decline1-6
OFEV® (nintedanib) is approved for the treatment of progressive fibrosing interstitial lung disease (PF-ILD).
systemic sclerosis-associated interstitial lung disease (SSc-ILD) and idiopathic pulmonary fibrosis (IPF).1
systemic sclerosis-associated interstitial lung disease (SSc-ILD) and idiopathic pulmonary fibrosis (IPF).1
CTD-ILD Pathophysiology & MoA
Document ID: PC-PH-103741
13/06/2022
Author: Boehringer Ingelheim
RELATED CONTENT
PC-PH-103741
Production date: June 2022
Production date: June 2022
